Seez launches the automotive industry's first GPT-powered chatbot for car dealerships in Europe and Middle East
Seez, the cutting-edge automotive tech start-up, is making waves with 'Seezar,' an innovative GPT-powered chatbot tailored for dealerships across Europe and the Middle East. This AI-driven solution is a game-changer, revolutionizing customer interactions and operations in the automotive sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230829087796/en/
(Graphic: Business Wire)
Trained on our AI modules and a vast automotive dataset, the GPT-powered bot delivers seamless responses and task execution across diverse subjects. Starting with Customer Support, Seezar's capabilities will soon extend to Sales and Lead Management, integrating seamlessly with dealer workflows.
Seezar integrates with our omnichannel showroom platform, SeezPad, incorporating Lead Management and CRM functionalities. This integration consolidates interactions, streamlining communication and enriching the customer journey. Dealerships leverage AI insights for targeted marketing, personalized recommendations, and enhanced customer support.
Seezar underscores Seez's commitment to harnessing AI's potential in the auto industry. Building on its 2017 chatbot Caesar's success, Seez empowers dealerships with AI-driven solutions that elevate experiences and drive sales.
Tarek Kabrit, Seez's CEO, states, “We launched an AI chatbot 6 years ago. It probably was too early - but now with the development in chatgpt, the increased level of digitisation at the dealerships and the openness of customers to complete big parts of their purchase online - we feel it all came together nicely to usher a new era in the way people search for and buy cars, and we are very glad to be playing a part in it.”
Crafted for dealerships in Europe and Middle East, Seezar overcomes traditional chatbot limitations, enhancing understanding and analytics. This innovation aligns with the industry's digital shift and AI adoption. The solution's initial phase excites waitlisted dealerships, gradually rolling out to the first group.
Seez's achievements span European expansion, Danish marketplace launch, first online car sold in Nordics, and partnerships with TRYG and Santander. Recent undisclosed funding fuels MENA and Europe growth, reinforcing AI dedication and launching GPT-powered automotive excellence.
The synergy of Seez's AI modules, with GPT-tech, positions Seezar at the forefront of innovation, enhancing omnichannel capabilities for dealers.
Read more:
Seez: https://seez.co/en/
Seezar: https://seezar.ai/
Press-only Internal Reveal video by CEO: https://youtu.be/GGq3YQZAq6U
In AI since 2017: https://www.entrepreneur.com/en-ae/technology/shazam-for-cars-ai-powered-seez-wants-to-change-the-way/300200
https://www.forbesmiddleeast.com/lists/50-most-funded-startups-2022/seez/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230829087796/en/
Contact information
Camilla Müller, B2B Marketing Manager at Seez
camilla@seez.dk - (45) 20 63 02 08
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom